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Summary
The adaptation of pancreatic islets to pregnancy includes increased  cell proliferation, expansion of islet mass, and increased insulin synthesis
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dnd secretion. Most of these adaptations are induced by prolactin (PRL). We have previously described that in vitro PRL treatment increases
RK3 expression in isolated rat pancreatic islets. This study shows that ERK3 is also upregulated during pregnancy. Islets from pregnant rats
reated with antisense oligonucleotide targeted to the PRL receptor displayed a significant reduction in ERK3 expression. Immunohistochemical
ouble-staining showed that ERK3 expression is restricted to pancreatic  cells. Transfection with antisense oligonucleotide targeted to ERK3
bolished the insulin secretion stimulated by glucose in rat islets and by PMA in RINm5F cells. Therefore, we examined the participation of ERK3
n the activation of a cellular target involved in secretory events, the microtubule associated protein MAP2. PMA induced ERK3 phosphorylation
hat was companied by an increase in ERK3/MAP2 association and MAP2 phosphorylation. These observations provide evidence that ERK3 is
nvolved in the regulation of stimulus-secretion coupling in pancreatic  cells.
2006 Elsevier Ireland Ltd. All rights reserved.
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. Introduction
The family of serine/threonine kinases known as extracel-
ular signal-regulated kinases (ERKs) is composed by a large
umber of ubiquitous proteins being activated by a variety of hor-
ones and growth factors (Pearson et al., 2001). In general, cell
timulation induces a signaling cascade that leads to phospho-
ylation of MEK (MAPK/ERK kinase), which, in turn, activates
RK via tyrosine and threonine phosphorylation (Robinson et
l., 2002). The p44/p42 MAPKs (ERK1/2) are expressed in
ancreatic  cell and regulate gene transcription and cell dif-
erentiation (Lingohr et al., 2002). Glucose, the main insulin
ecretagogue, induces phosphorylation of cytoplasmic proteins
nvolved in exocytosis of insulin-containing granules such as
∗ Corresponding author. Tel.: +55 11 30917961; fax: +55 11 30917285.
E-mail address: sbordin@icb.usp.br (S. Bordin).
synapsin I by activating the ERK1/2 cascade (Longuet et al.,
2005).
Prolactin (PRL) upregulates islet function by increasing (1)
insulin synthesis; (2) glucose uptake and metabolism; and (3)
glucose-induced insulin release with a reduced glucose stim-
ulation threshold (Sorenson et al., 1987a; Sorenson et al.,
1987b; Shao et al., 2004). These changes induced by PRL are
observed in vivo during early and late pregnancy (Weinhaus et
al., 1996). A cDNA array approach was carried out in order to
identify new proteins potentially involved in the insulin secre-
tory machinery. We have found that PRL treatment increases
ERK3 mRNA and protein content in isolated rat pancreatic
islets (Bordin et al., 2004). ERK3 is a distantly related mem-
ber of the mitogen-activated protein (MAP) kinase superfam-
ily (Pearson et al., 2001; Turgeon et al., 2002). ERK3 is
described as a highly unstable protein that is constitutively
degraded by the ubiquitin–proteasome pathway in proliferat-
ing cells (Coulombe et al., 2003). In the cytoplasm, ERK3 is
303-7207/$ – see front matter © 2006 Elsevier Ireland Ltd. All rights reserved.
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activated by the conventional PKC (Sauma and Friedman,
1996) and targets downstream activation of MAPK-activated
protein kinase-5 (MK5) (Seternes et al., 2004; Schumacher et al.,
2004).
In this study evidence is presented that ERK3 plays an impor-
tant role for the functioning of rat pancreatic islet. The following
aspects were examined: (i) the regulation of ERK3 expression by
PRL during pregnancy, (ii) the distribution of ERK3 among the
cell types of the pancreatic islet, (iii) the involvement of ERK3
in the glucose-induced insulin secretion, and (iv) the activation
of ERK3 by conventional PKC.
2. Materials and methods
2.1. Materials
Bovine serum albumin (BSA, fraction V), Ficoll, RPMI-1640 medium, col-
lagenase type V, and the chemicals used in the experiments for immunoblotting
were purchased from Sigma (St. Louis, MO, USA). LipofectamineTM 2000
Transfection Reagent and OPTI-MEM® I Reduced Serum Medium were pur-
chased from Invitrogen (Carlsbad, CA, USA). All plastics for cell culture
were obtained from TPP (Trasadingen, Switzerland). Nitrocellulose membranes
(Hybond N, 0.45m), protein A sepharose 6 MB, and the enhanced chemi-
luminescence reagent kit (ECL) were purchased from Amersham Pharmacia
Biotech (Uppsala, Sweden). The apparatus for SDS-PAGE and immunoblot-
ting were from Bio-Rad (Richmond, CA, USA). Antibodies against ERK3
(sc-156), MAP2 (sc-20172), and -Tubulin (sc-8035) were from Santa Cruz
Technology (Santa Cruz, CA, USA). The antibody against phospho-serine was
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sense 5′CAAGAAGGTCGGGATCGTCG and antisense 5′ACCAGGCAAG-
TCTCAGGAGGTG, 57 ◦C, 209 bp.
2.4. Immunostaining
The animals used for immunolabeling experiments (virgin Wistar female
rats) were perfused with saline and 2% paraformaldehyde in 0.1 M phosphate
buffer (PB) under ketamine/xylazine anesthesia and their pancreas postfixed
for 5–8 h. After cryoprotection with 30% sucrose in PB for 48 h, the pancreata
were sectioned (18m) on a cryostat and the sections immediately collected
in gelatin and chromoalumen-coated slides. The sections were incubated with
a combination of a guinea-pig polyclonal anti-insulin antibody (A-0564 from
Dako, Denmark) and a rabbit polyclonal anti-ERK3 antibody (sc-156) from
Santa Cruz Technology, both diluted 1:200 in PB with 0.3% Triton X-100.
Following three times of 10 min washes in PB, sections were incubated with a
mixture of a donkey anti-guinea-pig IgG labeled with fluorescein isothiocyanate
and a donkey anti-rabbit IgG labeled with tetramethyl rhodamine isothiocyanate
for 2 h (Jackson Laboratories, West Grove, PA, USA), both diluted at 1:50 in PB
with 0.3% Triton X-100. Sections were then washed three times for 10 min in
PB and coverslipped with glycerol-carbonate buffer. The material was analyzed
under a fluorescence microscope and images captured using a digital camera.
For control of immunostaining specificity, primary antibodies were replaced by
normal sera.
2.5. RINm5F cell culture and incubations
RINm5F cells were cultured as previously described (Wilson et al., 1999).
RPMI 1640-NaHCO3 medium supplemented with 10% bovine fetal serum,
11.1 mM glucose, penicillin G (100 IU), and streptomycin (100g ml−1), was
used. For immunoprecipitation assay, cells were previously washed for 10 min
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erom Chemicon (Temecula, CA, USA), the anti-ERK1/2 antibody was from
ell Signaling Technology (Beverly, MA, USA) and the anti-PRLR antibody
mouse IgG1 clone U5) was from Affinity Bioreagents (Golden, CO, USA). The
KC inhibitor G ¨O-6976 and phorbol-12-myristate-13-acetate (PMA) were from
albiochem (Darmstadt, Germany). The oligonucleotides for ERK3 knock-
own were manufactured by Integrated DNA Technologies (IDT, Coralville, IA,
SA).
.2. Prolactin receptor PRLR phosphorthioate oligonucleotide
reatment and islet isolation
Phosphorthioate-modified oligonucleotides were designed according to the
enbank accession M74152 from Rattus novergicus PRLR. We have already
etailed the treatment, the sequence of the antisense oligo and its in vivo
fficiency (Amaral et al., 2004). The experiments presented herein were per-
ormed with the same set of animals used in the previous study. Briefly, female
istar rats were injected (i.p.) with sense (SO-PRLR) and antisense (ASO-
RLR) oligonucleotides, respectively, during the 16th, 17th, and 18th days
f pregnancy. The rats were killed on the day 19 of pregnancy. For each set
f experiments, the islets were isolated from six rats by collagenase diges-
ion of pancreata and separated from pancreatic debris by centrifugation in
icoll gradient. The experiments involving animals were carried out in accor-
ance with the guidelines of the Brazilian College for Animal Experimentation
COBEA).
.3. RNA extraction and RT-PCR
Total RNA was extracted from approximately 400 islets using Trizol
eagent (Invitrogen). Conventional RT-PCR analysis was performed as previ-
usly described (Bordin et al., 2004). The amplification products were run
n a 1.5% agarose gel containing ethidium bromide, and the band intensities
ere determined by digital scanning followed by quantification using the Scion
mage analysis software (Scion Corp., Frederick, MD, USA). The results were
xpressed as a ratio of the target genes to the housekeeping RPL37a. The primer
equences used for RT-PCR analysis with their respective melting point and
engths were as follows: ERK3 sense 5′TGTTGTGAGGTCAGGAAGGACG
nd antisense 5′TGTCTTGTGAGGGATTTGAGGG, 57 ◦C, 309 bp; RPL37at 37 ◦C with Krebs-bicarbonate buffer containing 2.8 mM glucose. After that,
he cells were incubated in Krebs-bicarbonate buffer containing 2.8 mM glucose
nd G ¨O-6976 (1M) for 2 h and then acutely stimulated with PMA (0.5M)
or 20 min.
.6. Pancreatic islets and RINm5F transient transfection with
hosphorthioate oligonucleotide targeted to ERK3
Pancreatic islets from virgin Wistar rats and RINm5F cells were cultured in
pti-MEM containing 10 mM glucose plus a chimeric DNA-RNA 2′-O-methyl
hosphorthioate oligonucleotide targeted to ERK3, previously mixed with Lipo-
ectamine 2000 reagent. Islets and RINm5F cells were treated as follows: (1) with
ipofectamine 2000 reagent only (CTL), (2) with Lipofectamine 2000 mixed
ith a scrambled oligonucleotide (SO-ERK3), and (3) with Lipofectamine 2000
ixed with an antisense oligonucleotide (ASO-ERK3), and were incubated for
h in serum-deprived media. The medium was then supplemented with fetal
ovine serum (10%) and cultured overnight. Islets and RINm5F cells were
hen used for insulin secretion assay and conventional immunoblotting against
RK3 to check the efficiency of the blockade. After transfection, RINm5F
ells were also acutely stimulated with PMA (0.5M for 20 min) and used for
AP2 immunoprecipitation. The sequences of the SO-ERK3 and ASO-ERK3
ere, respectively, 5′-mCmAmUmCGGCCCAATGCmCmGmAmC, and 5′-
GmCmCmUCCACAGCCCAmAmUmGmG, where ‘m’ denotes RNA 2′-O-
ethyl nucleotides.
.7. Insulin secretion
Groups of five islets were first incubated for 30 min at 37 ◦C in Krebs-
icarbonate buffer containing 5.6 mM glucose and equilibrated with 95% O2/5%
O2, pH 7.4. The solution was then replaced by fresh Krebs-bicarbonate buffer
nd the islets were incubated for a further 30 min period with medium containing
.6 or 11.1 mM glucose.
The RINm5F cells were seeded in 24-well plates and grown to reach near
onfluency. At the day of the experiment, the cells were first incubated for
0 min at 37 ◦C in Krebs-bicarbonate buffer containing 2.8 mM glucose and
quilibrated with 95% O2/5% CO2, pH 7.4. The solution was then replaced
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with fresh Krebs-bicarbonate buffer and the islets were incubated for a fur-
ther 1 h period with medium containing 2.8 mM glucose plus DMSO or
PMA.
The cumulative insulin released from islets (30 min) or RINm5F cells (1 h)
was determined by RIA using rat insulin as standard.
2.8. Nuclear and cytosolic protein extraction
RINm5F cells were suspended in 150l of cell lysis buffer (10 mM Tris,
pH 8.0, 10 mM NaCl, 0.2% Nonidet-P40) containing phosphatase and protease
inhibitors (sodium orthovanadate, phenylmethylsulfonyl fluoride, and apro-
tinin). After 10 min of incubation on ice, the samples were centrifuged at
2500 × g for 15 min at 4 ◦C. The supernatant was removed and used as the
cytosolic protein fraction. The pellets of nuclei were suspended in 100l of
nuclear lysis buffer (20 mM Tris, pH 8.0, 10 mM EDTA, 1% SDS, and phos-
phatase and protease inhibitors) and incubated on ice for 10 min. The samples
were centrifuged at 12,000 × g for 15 min to remove debris and the supernatant
was used as nuclear protein fraction.
2.9. Protein analysis by Western blotting
Islets and RINm5F cells were processed for protein extraction as pre-
viously described (Amaral et al., 2004). For immunoprecipitation, RINm5F
samples were incubated with anti-ERK3 or anti-MAP2 antibodies and pro-
cessed as previously published (Anheˆ et al., 2004). Immunoprecipitates and
protein samples were resolved in an 8% SDS-PAGE and transferred to nitro-
cellulose membrane (Amaral et al., 2004). The membranes were incubated for
4 h at 22 ◦C with antibodies against phospho-serine (1:1000), ERK3 (1:1000),
ERK1/2 (1:2000), -Tubulin (1:500), PRLR (1:2000), or MAP2 (1:500) diluted
in blocking buffer with 3% non-fat dried milk, and then washed for 30 min
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In order to confirm the participation of PRL on ERK3 expres-
sion during pregnancy, pregnant and virgin rats were treated with
a phosphorthioate-modified oligonucleotide targeted to the rat
PRLR mRNA sequence. The efficiency of ASO-PRLR treat-
ment to reduce PRLR levels in pancreatic islets from pregnant
rats is shown in Fig. 1C. Pregnancy was associated with an
increase in ERK3 expression (by 198%; P < 0.05 versus CTL
treated with SO-PRLR) that was abrogated by PRLR knock-
down (by 66%; P < 0.05 versus pregnant treated with SO-PRLR)
(Fig. 1D).
3.2. ERK3 expression in pancreatic islets from adult rats is
restricted to β-cells
A double-staining immunohistochemical approach using
anti-ERK3 and insulin antibodies allowed us to determine the
distribution of ERK3 in rat pancreatic islets. Staining over-
lapped for insulin (green) and for ERK3 (red), indicating that
the expression of ERK3 is restricted to the pancreatic -cells
(Fig. 2).
3.3. ERK3 knockdown prevents glucose-induced insulin
secretion in isolated pancreatic islets and PMA-induced
insulin secretion in RINm5F cells
The PRLR-associated upregulation of ERK3 expression in
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wn blocking buffer without milk. The blots were subsequently incubated with
eroxidase-conjugated secondary antibody for 1 h. Visualization of specific pro-
ein bands was performed by using the enhanced chemiluminescence reagent
it (ECL, Amersham Pharmacia Biotech) with exposure to photographic film.
he band intensities were quantified by optical densitometry (Scion Image,
rederick, MD).
.10. Statistical analysis
Mean values ± S.E.M. obtained from densitometric scans were compared
sing Tukey–Kramer test (ANOVA) and the unpaired Student’s test when appro-
riate. P-values <0.05 indicated significant differences.
. Results
.1. Increased ERK3 expression in pancreatic islets from
regnant rats is modulated by PRL receptors
We have previously demonstrated that isolated pancreatic
slets treated with PRL display an increase in ERK3 mRNA
nd protein levels (Bordin et al., 2004). The present study
hows that pancreatic islets freshly isolated from rats on the
ay 19 of pregnancy also present increased ERK3 expression.
he increase in ERK3 expression is observed at the mRNA
by 27%; P < 0.05) (Fig. 1A) and at the protein levels (by
00%; P < 0.05) (Fig. 1B). ERK3 degradation is proposed to be
apidly triggered by the ubiquitin/proteasome proteolytic path-
ay (Coulombe et al., 2003) and by direct action of caspases
Bind et al., 2004). Since placental lactogen and prolactin are
ble to downregulate caspase activity (Fernandez et al., 2003;
essier et al., 2001), the difference between the ERK3 mRNA
nd protein levels may be a result of reduced ERK3 protein
egradation.ancreatic islets of pregnant rats together with the specific local-
zation of ERK3 in the pancreatic -cells led us to investigate
he participation of ERK3 in the insulin secretory response. Iso-
ated pancreatic islets and RINm5F cells were transfected with
himeric phosphorthioate oligonucleotide targeted to the ERK3
RNA sequence (Fig. 3A). The control-scrambled oligonu-
leotide (SO-ERK3) did not interfere with the ERK3 lev-
ls whereas the ERK3 ASO promoted a reduction (by 75%
ersus CTL and by 60% versus SO-ERK3; P < 0.05). The
ntisense oligonucleotide target to the ERK3 sequence was
roved to be specific because the protein levels of ERK1/2
emained unchanged (Fig. 3A). Transfection of RINm5F
ells exhibited the same efficiency of blockade (data not
hown).
Control and SO transfected islets showed an increase in
nsulin secretion when exposed to 11.1 mM glucose (by 58%
nd 57%, respectively; P < 0.05 versus 5.6 mM glucose). ERK3
lockade abolished the insulin secretion induced by 11.1 mM
lucose in rat pancreatic islets but had no effect on 5.6 mM glu-
ose (Fig. 3B).
Although not responsive to glucose, RINm5F cells have
een used as a model to study phorbol-12-myristate-13-acetate
PMA)-induced insulin secretion (Wilson et al., 1999; Dunne,
994). PMA is a potent stimulator of -cell insulin secre-
ion (Yaney et al., 2002); the mechanism underlying this
ffect of PMA relies on its ability to replace DAG in tar-
eting conventional and novel PKC isoforms (Easom et al.,
989). Since ERK3 is likely a downstream target of PKC we
ested whether ERK3 could participate in PMA-induced insulin
ecretion. RINm5F cells untransfected (CTL) and transfected
ith SO and ASO targeted to ERK3 were then stimulated
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Fig. 1. Expression of ERK3 in rat pancreatic islets and its regulation by prolactin receptor. Islets were isolated from virgin female (CTL) and pregnant (Preg) rats.
Total RNA (A) and protein (B) were used for RT-PCR analysis of ERK3 mRNA expression and Western blot analysis of ERK3, respectively. Islets were isolated
from pregnant and CTL rats treated with SO-PRLR and ASO-PRLR oligonucleotides targeted to the rat PRL receptor. The protein was extracted and processed for
immunobloting against PRLR, -Tubulin (C) and ERK3 (D). The bars represent the relative expression of ERK3 as determined by optical densitometry and are
presented as mean ± S.E.M. *P < 0.05 vs. CTL. #P < 0.05 vs. CTL + SO-PRLR. ##P < 0.05 vs. Pregnant + SO-PRLR.
with PMA 0.5M to assay insulin secretion. Both CTL and
SO transfected cells exhibited an increase in insulin secretion
in the presence of PMA (by 131% and 196%, respectively;
P < 0.05 versus 2.8 mM glucose without PMA). This incre-
ment was abolished by ERK3 knockdown in ASO transfected
cells. Neither the SO nor the ASO transfected cells showed
any difference in basal (glucose 2.8 mM) insulin secretion
(Fig. 3C).
Fig. 2. Distribution of ERK3 in rat pancreatic islets. The pancreata were sectioned and used for double staining against insulin and ERK3. The staining was visualized
in a confocal microscope. Left panel shows the staining for insulin (green) and the middle panel shows the staining for ERK3 in the same islet (red). The right panel
represents the overlapping of both images (yellow).
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Fig. 3. Participation of ERK3 in insulin secretion by pancreatic islets and
RINm5F cells. (A) Groups of 150–200 pancreatic islets from rats (CTL) were
cultured overnight and transiently transfected with scrambled (SO-ERK3) or
antisense (ASO-ERK3) oligonucleotides against ERK3. After 24 h of culture,
islets were used for immunobloting against ERK3 (B) or insulin secretion
assay (C) RINm5F cells were grown in 24-well plates to 105 cells/well and
transiently transfected with scrambled (SO-ERK3) or antisense (ASO-ERK3)
oligonucleotides against ERK3. After 24 h of culture the cells were used for
insulin secretion assay. The results represent the relative expression of ERK3
as determined by optical densitometry for the immunobloting and the cumu-
lative insulin secretion during 30 min (islets) or 1 h (RINm5F cells), and are
presented as mean ± S.E.M. *P < 0.05 vs. CTL and SO-ERK3. #P < 0.05 vs.
CTL in 5.6 mM glucose. ##P < 0.05 vs. SO-ERK3 in 5.6 mM glucose. &P < 0.05
vs. CTL in 2.8 mM glucose without PMA. &&P < 0.05 vs. SO-ERK3 in 2.8 mM
glucose without PMA.
Fig. 4. Localization of ERK3 isoforms in RINm5F cells. Total (1), cytoplasmatic
(2), and nuclear (3) fractions from protein extract of RINm5F cells were resolved
in 8% SDS-PAGE together with the protein eluted from MAP2 immunoprecip-
itates (4) (see Section 2). The membrane was probed with anti-ERK3 antibody.
3.4. ERK3 distribution in RINm5F cell compartments and
PMA-stimulated ERK3 serine phosphorylation and
association with microtubule-associated protein 2 (MAP2)
A recent study reported that rat ERK3 has nuclear (∼63 kDa)
and cytoplasmic (∼97 kDa) forms. Rat insulinoma lineage
RINm5F cells contain both forms of ERK3 (Fig. 4). As reported
for other cell types (Bind et al., 2004), p63-ERK3 is an exclusive
nuclear form of this MAPK and it is not found in the cytoso-
lic fraction. The p97-ERK3 is detected in both cytoplasmic and
nuclear fractions. It is possible that the presence of p97-ERK3
in the nuclear fraction results from an active nuclear import
(Julien et al., 2003). Additionally, p97-MAP2 associates with
the microtubule-associated protein 2 (MAP2) (Fig. 4).
MAP2 is a member of a larger family of microtubule-
associated proteins that, upon phosphorylation, have the ability
to regulate reversible polymerization and stability of micro-
tubules through their affinity for tubulin (Sloboda et al., 1976)
as well as their interaction with other cellular structures such as
actin (Sattilaro, 1986). MAP Kinases such as JNK and ERK1/2
have been reported to associate with and consequently phospho-
rylate MAP2 (Chang et al., 2003; Cobb et al., 1991). Attempting
to find out a possible mechanism to explain ERK3 participa-
tion in insulin secretion we tested whether PMA could promote
ERK3 serine phosphorylation and association with MAP2.
PMA induced an increase in ERK3 serine phosphorylation
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Cby 40%; P < 0.05). This effect was abolished by addition of the
KC inhibitor G ¨O-6976. The increase in ERK3 phosphorylation
as not associated with changes in ERK3 content (Fig. 5A).
ogether with ERK3 phosphorylation, PMA was able to induce
KC dependent ERK3/MAP2 association (an increase of 60%;
< 0.05) (Fig. 5B).
.5. ERK3 knockdown blockades PMA-induced MAP2
erine phosphorylation in RINm5F cells
MAP2 is efficiently phosphorylated in serine residues by sev-
ral classes of Ser/Thr protein kinases in vitro, including cAMP-
ependent protein kinase (PKA) (Sloboda et al., 1975), MAPKi-
ases, such as ERK1/2 (Quinlan and Shelley, 1996; Sanchez et
l., 1995) and protein kinase C (PKC) (Walaas and Nairn, 1989).
onsidering the above results showing ERK3 phosphorylation
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Fig. 5. PMA-induced p97-ERK3 serine phosphorylation and association with
MAP2. RINm5F cells were incubated in Krebs-bicarbonate buffer (2.8 mM glu-
cose) and the vehicle 0.3% DMSO or the PKC inhibtor G ¨O-6976 (0.5M). After
1 h, the solution was replaced by fresh medium for 30 min with 0.3% DMSO
or 0.5M PMA (PMA). Cell extracts were processed for ERK3 immunopre-
cipitation (Section 2). The membranes were probed with anti-phospho-serine,
anti-ERK3 (A) and anti-MAP2 (B) antibodies. The results are presented as
mean ± S.E.M. and represent the relative phosphorylation of ERK3 and the
amount of MAP2 associated with ERK3. *P < 0.05 vs. CTL, G ¨O-6976, and
PMA + G ¨O-6976.
and association with MAP2 after conventional PKC activation
by PMA, we investigated whether ERK3 could mediate PMA-
induced MAP2 serine phosphorylation. PMA induced MAP2
serine phosphorylation in RINm5F cells (Fig. 6). This effect is
completely blocked by the knockdown of ERK3 expression.
4. Discussion
Pregnancy induces peripheral insulin resistance, which is nor-
mally compensated by increased  cell proliferation, expansion
of islet volume, and increased insulin synthesis and secretion.
Several experiments performed both in vitro and in vivo have
shown that lactogenic hormone treatment induces the same
changes in islets as those observed during pregnancy (Sorenson
Fig. 6. ERK3 knockdown blockades PMA-induced MAP2 serine phosphory-
lation. RINm5F cells were transiently transfected with antisense (ASO-ERK3)
oligonucleotides against ERK3. After 24 h of culture, untransfected and ASO-
ERK3 transfected cells were incubated in Krebs-bicarbonate buffer (2.8 mM
glucose) for 20 min containing the vehicle 0.3% DMSO or 0.5M PMA. Cell
extracts were processed for MAP2 immunoprecipitation. The membranes were
probed with anti-phospho-serine and anti-MAP2 antibodies. The results are pre-
sented as mean ± S.E.M. and represent the relative phosphorylation of MAP2.
*P < 0.05 vs. CTL treated with the vehicle.
et al., 1987a; Sorenson et al., 1987b; Nielsen et al., 1999). The
present results show for the first time that PRL regulates ERK3
expression in an in vivo model of increased insulin secretion.
PRL regulation of ERK3 expression and its specific location in
pancreatic  cells led us to investigate the participation of ERK3
in the insulin secretion process.
ERK1 and ERK2 are activated by phosphorylation on tyro-
sine and threonine by a well known pathway through MEK and
MEK Kinase (Seger and Krebs, 1995). In contrast, ERK3 is
the unique MAPK that contains a single phosphorylation site
(serine 189) in its activation loop (Prowse and Lew, 2001). Infor-
mation regarding upstream activation of ERK3 shows that this
MAPK seems to be activated by conventional PKC (Sauma
and Friedman, 1996). Considering the present results that ERK3
knockdown abolished both glucose and PMA-induced insulin
secretion by pancreatic  cells, it is likely that ERK3 plays an
important role in the glucose-induced insulin secretion through
PKC activation.
Although both human and mouse ERK3 proteins have essen-
tially identical amino acid sequence encoding a 721-amino acid
protein of approximately 100 kDa (Zhu et al., 1994), the rat
orthologue ERK3 gene was first reported to encode a unique 62-
kDa protein containing 543 amino acids (Boulton et al., 1991)
Recently, in vitro translation of the rat and human ERK3 cDNAs
reconciled the rat protein sequence with that of the mouse and
human and revealed that both genes encoded proteins of the same
m
rolecular weight (±100 kDa) (Bind et al., 2004). Information
egarding subcellular localization was also initially controver-
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sial. An initial study described ERK3 as a constitutively nuclear
protein kinase (Cheng et al., 1996). A later report however
demonstrated that the 100 kDa endogenous rat and human ERK3
is a Golgi-resident cytoplasmic protein, whereas the nuclear
form of ERK3 is likely to be between 45 and 68 kDa that results
from the degradation of the heavier isoform (Bind et al., 2004).
Our Western blot analysis showed the presence of both nuclear
and cytoplasmic ERK3 isoforms in rat pancreatic  cells. The
cytoplasmic ERK3 isoform is phosphorylated on serine residues
via conventional PKC activation. In addition to the increased
ERK3 phosphorylation by PKC, the present results also show
that the stimulation of conventional PKC pathway increases the
phosphorylation of MAP2 associated with ERK3. Therefore, the
complex ERK3/MAP2 formed after PMA stimulus might play
an important part for the mechanism by which ERK3 modulates
insulin secretion.
The acronym MAPKs is derived not only from mitogen-
activated protein kinases but also from microtubule-associated
protein kinases. MAPKs were initially discovered in association
with the cytoskeleton and were later found to be implicated in the
regulation of nuclear transcript events. In insulin-secreting cells,
the best studied MAPKs ERK1/2 are activated by high glucose
concentrations. However, a close relationship between ERK1/2
activity and insulin release has not been consistently demon-
strated. First, stimulation of insulin secretion after glucose-
induced ERK1/2 activation varies among different types of cell
l
a
i
i
(
a
1
i
B
e
o
k
i
p
i
a
M
d
o
r
p
M

1
t
b
u
M
p
C
cose and modulates insulin secretion by activation of MAP-2 and
synapsin-1 (Easom, 1999), but the regulation of the molecular
motor activity during insulin-containing granules exocytosis is
poorly understood.
The microtubule-associated protein MAP2 is efficiently
phosphorylated by several protein kinases, including MAPKs
(Karin, 1995; Gupta et al., 1996), as observed for the JNK
family. Following activation, a portion of the activated JNK
enters the nucleus, resulting in phosphorylation of several tran-
scription factors, including c-Jun, ATF-2, and Elk-1 (Chang et
al., 2003; Cobb et al., 1991). However, another pool of JNK
(mainly JNK1) directly phosphorylates and activates MAP2 and
MAP1b, which result in modulation of microtubule dynamics.
The ability of JNK to phosphorylate MAP2 is additionally sup-
ported by JNK1/MAP2 co-immunoprecipitation (Chang et al.,
2003). MAPK signaling to MAPs is also involved in regula-
tion of cytoskeleton in nonneuronal cells in various conditions
(Minshull et al., 1994; Takenaka et al., 1998) but the mechanisms
underlying this function of MAPKs is still unclear.
Various studies have shown that overexpression of MAPs in
fibroblasts and neurons causes inhibition of plus-end-directed
microtubule transport (Mandelkow et al., 2004). For instance,
mitochondria accumulate within the cell body and its move-
ment through the axons is impaired when tau protein is over-
expressed. Other MAPs such as MAP4 and MAP2c similarly
inhibit motor-based transport, with the severity of the inhibition
b
p
e
c
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t
d
p
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s
f
m
r
a
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a
(
c
m
r
a
m
t
sineages (Khoo and Cobb, 1997; Benes et al., 1998; Longuet et
l., 2005). Second, in pancreatic islets, ERK1/2 phosphorylation
s completely prevented by the treatment with the selective MEK
nhibitor PD98059, whereas insulin response is partially reduced
Longuet et al., 2005). Considering the findings that ERK1/2
re activated by stimuli that do not elicit secretion (Frodin et al.,
995), and that the increase in ERK1/2 activity is related to the
nduction of several genes, including insulin (Frodin et al., 1995;
enes et al., 1999), it is likely that the transcriptional machin-
ry is the most relevant target of ERK1/2. Thus, the abolition
f glucose- and PMA-stimulated insulin secretion after ERK3
nockdown showed herein support the proposition that ERK3,
nstead of ERK1/2, is a MAPK preferentially involved in the
rocess of insulin-containing granule exocytosis.
It is well known that the regulation of microtubule polymer-
zation is directly mediated by a large family of microtubule-
ssociated proteins (MAPs) (Desai and Mitchison, 1997).
icrotubules often undergo rapid transitions between stable and
ynamic forms as a result of continuous growing and shrinking
f their ends. This phenomenon, termed dynamic instability,
egulates several cellular processes such as intracellular trans-
ort, cell motility, mitosis, and differentiation (Kirschner and
itchison, 1986). The involvement of microtubule-dependent
cell secretory activity has been well established (Lacy et al.,
972; Pipeleers et al., 1976; Somers et al., 1979), and the par-
icipation of MAPs in the insulin secretion process is supported
y the evidence that isolated insulin-containing secretory gran-
les interact with microtubules in the presence of exogenous
APs only (Suprenant and Dentler, 1982). It has been pro-
osed that the activation of CaM kinase II, a multifunctional
a2+/calmodulin-dependent protein kinase, is stimulated by glu-eing correlated with the strength of the binding affinity of the
articular MAP. Mandelkow et al. (2004) have shown that over-
xpression of the microtubule affinity regulating kinase MARK
auses phosphorylation of MAPs, which in turn impairs their
ssociation with microtubules. Inhibition of transport by overex-
ression of tau is then relieved by MARK overexpression. Based
n these observations, Baas and Qiang (2005) hypothesized that
he levels of various cytoskeletal proteins and relevant kinases
ight regulate MAPs by phosphorylation and then determine the
requency by which motor-based transport events occur within
he microtubule. We therefore propose that ERK3 might act as
ominant kinase for MAP2 in pancreatic  cell, inasmuch its
hosphorylation is accompanied by its association with MAP2,
nd ERK3 knockdown markedly reduced PMA-induced MAP2
hosphorylation and, consequently, insulin secretion.
Our study is not the first to correlate MAP2 with insulin
ecretion. Krueger et al. (1997) have shown that different iso-
orms of MAP2 are expressed in pancreatic islets. The high-
olecular mass form of MAP2 is preferentially expressed in
at insulinoma TC3 cells, and is positively regulated by Ca2+
nd CaM kinase II. In the present study, the expression of
he small MAP2 isoform termed MAP2c was observed, prob-
bly due to the specificity of the antibody used. Krueger et al.
1997) showed the presence of an unidentified phosphoprotein
o-immunoprecipitated with the large MAP2 that has identical
igration pattern observed in our experiments. The phospho-
ylation status of this small co-immunoprecipitated protein is
lso regulated by Ca2+ in a time- and concentration-dependent
anner. Based on these observations, we do not exclude the par-
icipation of other MAP2 isoforms in ERK3-mediated insulin
ecretion.
40 G.F. Anheˆ et al. / Molecular and Cellular Endocrinology 251 (2006) 33–41
In summary, our study is the first to show that ERK3 expres-
sion is modulated by PRL in an in vivo model of increased
insulin secretion. We also describe the presence of ERK3 in
pancreatic -cells and demonstrate its involvement in glucose-
and PMA-induced insulin release. Additionally, we propose a
possible mechanism for the ERK3 participation in pancreatic
islet physiology. This mechanism involves activation of the con-
ventional PKC leading to ERK3 serine phosphorylation and
association with MAP2. The expression of ERK3, and possi-
bly the formation of the ERK3/MAP2 complex, is necessary for
MAP2 phosphorylation after PKC activation.
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